Information Regarding UCB as an Issuer by Virtue of Articles 15 and 18 of the Law of 2 May 2007 on the Disclosure of Major Holdings, as of 1 September 2008

Brussels, Belgium, September 12, 2008 - 6:00 pm CET -press release, regulated information - According to article 29 of the law of 2 May 2007 on the disclosure of major holdings, UCB releases the following information:

1. Information to be provided for on the basis of article 15, §1, al. 1

- Total of the share capital : EUR 550.095.156

- Total number of financial instruments that are treated as voting securities: 183.365.052 (single class of financial instruments)

- Total number of voting rights : 183.365.052 (single class of voting rights)

2. Additional information to be provided for on the basis of article 15, §1, al. 2

- Total number of convertible obligations : 0

- Total number of rights (materialized or not in financial instruments) to subscribe to yet un-issued financial instruments treated as voting securities:

• 209.000 warrants, giving, in case they are all exercised, a total number of 209.000 voting rights
• 30.000.000 conditional and defensive warrants, giving, in case they are all exercised, a total number of 30.000.000 voting rights

- Total number of shares without voting rights : 0

3. Information to be provided for on the basis of article 18, §1

- Threshold  provided for in the articles of association of UCB and in conformity with article 18, §1, al. 2 : 3%

4. Person to whom the notifications should be sent

- Ms Michèle de Cannart, Vice President & General Secretary

- Address : Allée de la Recherche 60, 1070 Brussels, Belgium

- Phone : +32 2 559 94 83  /  Fax : +32 2 559 98 00

- E-mail : michele.decannart@ucb-group.com 

Further information

Antje Witte, Vice-President Corporate Communications & Investor Relations
T +32.2.559.9346, Antje.witte@ucb-group.com

About UCB

UCB, Brussels, Belgium (www.ucb-group.com) is a global leader in the biopharmaceutical industry dedicated to the research, development and commercialisation of innovative medicines with focus on the fields of central nervous system and immunology disorders. Employing around 12 000 people in over 40 countries, UCB achieved revenue of 3.6 billion euro in 2007. UCB is listed on Euronext Brussels (symbol: UCB).